Isocitrate Dehydrogenase
"Isocitrate Dehydrogenase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme of the oxidoreductase class that catalyzes the conversion of isocitrate and NAD+ to yield 2-ketoglutarate, carbon dioxide, and NADH. It occurs in cell mitochondria. The enzyme requires Mg2+, Mn2+; it is activated by ADP, citrate, and Ca2+, and inhibited by NADH, NADPH, and ATP. The reaction is the key rate-limiting step of the citric acid (tricarboxylic) cycle. (From Dorland, 27th ed) (The NADP+ enzyme is EC 1.1.1.42.) EC 1.1.1.41.
Descriptor ID |
D007521
|
MeSH Number(s) |
D08.811.682.047.820.475
|
Concept/Terms |
Isocitrate Dehydrogenase- Isocitrate Dehydrogenase
- Dehydrogenase, Isocitrate
- NAD Isocitrate Dehydrogenase
- Dehydrogenase, NAD Isocitrate
- Isocitrate Dehydrogenase, NAD
- Isocitrate Dehydrogenase (NAD+)
|
Below are MeSH descriptors whose meaning is more general than "Isocitrate Dehydrogenase".
Below are MeSH descriptors whose meaning is more specific than "Isocitrate Dehydrogenase".
This graph shows the total number of publications written about "Isocitrate Dehydrogenase" by people in this website by year, and whether "Isocitrate Dehydrogenase" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2011 | 0 | 1 | 1 | 2012 | 3 | 1 | 4 | 2015 | 3 | 0 | 3 | 2016 | 1 | 3 | 4 | 2017 | 3 | 0 | 3 | 2018 | 5 | 1 | 6 | 2019 | 2 | 2 | 4 | 2020 | 3 | 1 | 4 | 2021 | 1 | 1 | 2 | 2022 | 0 | 2 | 2 | 2023 | 0 | 1 | 1 | 2024 | 2 | 2 | 4 | 2025 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Isocitrate Dehydrogenase" by people in Profiles.
-
Huang Y, Shan Y, Zhang W, Printzis C, Pesce L, Stover D, Stanhope C, Stranger BE, Huang RS. Sex differences in the molecular profile of adult diffuse glioma are shaped by IDH status and tumor microenvironment. Neuro Oncol. 2025 Feb 10; 27(2):430-444.
-
Stiff A, Fornerod M, Kain BN, Nicolet D, Kelly BJ, Miller KE, Mr?zek K, Boateng I, Bollas A, Garfinkle EAR, Momoh O, Fasola FA, Olawumi HO, Mencia-Trinchant N, Kloppers JF, van Marle AC, Hu E, Wijeratne S, Wheeler G, Walker CJ, Buss J, Heyrosa A, Desai H, Laganson A, Hamp E, Abu-Shihab Y, Abaza H, Kronen P, Sen S, Johnstone ME, Quinn K, Wronowski B, Hertlein E, Miles LA, Mims AS, Oakes CC, Blachly JS, Larkin KT, Mundy-Bosse B, Carroll AJ, Powell BL, Kolitz JE, Stone RM, Duarte C, Abbott D, Amaya ML, Jordan CT, Uy GL, Stock W, Archer KJ, Paskett ED, Guzman ML, Levine RL, Menghrajani K, Chakravarty D, Berger MF, Bottomly D, McWeeney SK, Tyner JW, Byrd JC, Salomonis N, Grimes HL, Mardis ER, Eisfeld AK. Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia. Nat Genet. 2024 Nov; 56(11):2434-2446.
-
Massaad E, Smith WJ, Bradley J, Esposito E, Gupta M, Burns E, Burns R, Velarde JK, Berglar IK, Gupta R, Martinez-Lage M, Dietrich J, Lennerz JK, Dunn GP, Jones PS, Choi BD, Kim AE, Frosch M, Barker FG, Curry WT, Carter BS, Nahed BV, Cahill DP, Shankar GM. Radical surgical resection with molecular margins is associated with improved survival in IDH wild-type glioblastoma. Neuro Oncol. 2024 Sep 05; 26(9):1660-1669.
-
Kalter JA, Yang RA, Toland A, Milla S, Lund TC, Hankinson T, Dahl NA. IDH-mutant astrocytoma arising from a demyelinating plaque in a child with X-linked adrenoleukodystrophy. J Neuropathol Exp Neurol. 2024 03 20; 83(4):289-292.
-
Malta TM, Sabedot TS, Morosini NS, Datta I, Garofano L, Vallentgoed W, Varn FS, Aldape K, D'Angelo F, Bakas S, Barnholtz-Sloan JS, Gan HK, Hasanain M, Hau AC, Johnson KC, Cazacu S, deCarvalho AC, Khasraw M, Kocakavuk E, Kouwenhoven MCM, Migliozzi S, Niclou SP, Niers JM, Ormond DR, Paek SH, Reifenberger G, Sillevis Smitt PA, Smits M, Stead LF, van den Bent MJ, Van Meir EG, Walenkamp A, Weiss T, Weller M, Westerman BA, Ylstra B, Wesseling P, Lasorella A, French PJ, Poisson LM, Verhaak RGW, Iavarone A, Noushmehr H. The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen. Cancer Res. 2024 03 04; 84(5):741-756.
-
Kleinschmidt-DeMasters BK, Ormond DR. Leptomeningeal metastases and dural spread in adult high-grade astrocytomas. J Neuropathol Exp Neurol. 2023 02 21; 82(3):194-201.
-
Pollyea DA, DiNardo CD, Arellano ML, Pigneux A, Fiedler W, Konopleva M, Rizzieri DA, Smith BD, Shinagawa A, Lemoli RM, Dail M, Duan Y, Chyla B, Potluri J, Miller CL, Kantarjian HM. Impact of Venetoclax and Azacitidine in Treatment-Na?ve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations. Clin Cancer Res. 2022 07 01; 28(13):2753-2761.
-
Varn FS, Johnson KC, Martinek J, Huse JT, Nasrallah MP, Wesseling P, Cooper LAD, Malta TM, Wade TE, Sabedot TS, Brat D, Gould PV, W?ehrer A, Aldape K, Ismail A, Sivajothi SK, Barthel FP, Kim H, Kocakavuk E, Ahmed N, White K, Datta I, Moon HE, Pollock S, Goldfarb C, Lee GH, Garofano L, Anderson KJ, Nehar-Belaid D, Barnholtz-Sloan JS, Bakas S, Byrne AT, D'Angelo F, Gan HK, Khasraw M, Migliozzi S, Ormond DR, Paek SH, Van Meir EG, Walenkamp AME, Watts C, Weiss T, Weller M, Palucka K, Stead LF, Poisson LM, Noushmehr H, Iavarone A, Verhaak RGW. Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell. 2022 06 09; 185(12):2184-2199.e16.
-
Cano M, Datta S, Wang L, Liu T, Flores-Bellver M, Sachdeva M, Sinha D, Handa JT. Nrf2 deficiency decreases NADPH from impaired IDH shuttle and pentose phosphate pathway in retinal pigmented epithelial cells to magnify oxidative stress-induced mitochondrial dysfunction. Aging Cell. 2021 08; 20(8):e13444.
-
Stein EM, DiNardo CD, Fathi AT, Mims AS, Pratz KW, Savona MR, Stein AS, Stone RM, Winer ES, Seet CS, D?hner H, Pollyea DA, McCloskey JK, Odenike O, L?wenberg B, Ossenkoppele GJ, Patel PA, Roshal M, Frattini MG, Lersch F, Franovic A, Nabhan S, Fan B, Choe S, Wang H, Wu B, Hua L, Almon C, Cooper M, Kantarjian HM, Tallman MS. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021 04 01; 137(13):1792-1803.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|